Correspondence | Published:

Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells

Bone Marrow Transplantation (2019) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Sasine JP, Schiller GJ. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. Blood Rev. 2015;29:1–9.

  2. 2.

    Fan M, Li M, Gao L, Geng S, Wang J, Wang Y, et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. J Hematol Oncol. 2017;10:151.

  3. 3.

    Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10:4.

  4. 4.

    Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76:1578–90.

  5. 5.

    Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T Cells With combinatorial antigen-sensing circuits. Cell. 2016;164:770–9.

  6. 6.

    Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29:1637–47.

  7. 7.

    Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol. 2015;22:484–8.

  8. 8.

    Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.

  9. 9.

    Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350:aab4077.https://doi.org/10.1126/science.aab4077.

    • 10.

      Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, et al. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res. 2013;37:1021–6.

    Download references

    Acknowledgements

    The authors thank all members of the study team, the patient, and their family. This work was supported by the research grants from the National Key R&D Program of China (2016YFC0902800), National natural science Foundation of China (81873443, 81270645, 81400155, 81500146), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province (BE2017655), Jiangsu Provincial Medical Talent (ZDRCA2016045), Jiangsu Natural Science Foundation of China (BK20140374) and Top-notch young health talents(to CQ), 5th Suzhou health professionals program.

    Author information

    1. These authors contributed equally: Changju Qu, Zheng Li, Liqing Kang

    2. These authors jointly supervised this work: Xiaowen Tang, Depei Wu

    Affiliations

    1. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 215000, Suzhou, China

      • Changju Qu
      • , Zheng Li
      • , Haiping Dai
      • , Jia Yin
      • , Guanghua Chen
      • , Mingqing Zhu
      • , Li Yao
      • , Ting Xu
      • , Xiaopeng Tian
      • , Yang Xu
      • , Jia Chen
      • , Xiaming Zhu
      • , Depei Wu
      •  & Xiaowen Tang

    2. Institute of Blood and Marrow Transplantation, 215000, Suzhou, China

      • Changju Qu
      • , Zheng Li
      • , Haiping Dai
      • , Jia Yin
      • , Guanghua Chen
      • , Mingqing Zhu
      • , Li Yao
      • , Ting Xu
      • , Xiaopeng Tian
      • , Yang Xu
      • , Jia Chen
      • , Xiaming Zhu
      • , Depei Wu
      •  & Xiaowen Tang

    3. Collaborative Innovation Center of Hematology, Soochow University, 215123, Suzhou, China

      • Changju Qu
      • , Zheng Li
      • , Haiping Dai
      • , Jia Yin
      • , Guanghua Chen
      • , Mingqing Zhu
      • , Li Yao
      • , Ting Xu
      • , Xiaopeng Tian
      • , Yang Xu
      • , Jia Chen
      • , Xiaming Zhu
      • , Depei Wu
      •  & Xiaowen Tang

    4. College of Chemistry and Molecular Engineering, East China Normal University, 200062, Suzhou, China

      • Liqing Kang
      •  & Lei Yu

    5. Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, 201203, Suzhou, China

      • Liqing Kang
      •  & Lei Yu

    6. Department of Hematology, The First People’s Hospital of Lianyungang, 222061, Suzhou, China

      • Ying Wang

    Authors

    1. Search for Changju Qu in:

    2. Search for Zheng Li in:

    3. Search for Liqing Kang in:

    4. Search for Ying Wang in:

    5. Search for Haiping Dai in:

    6. Search for Jia Yin in:

    7. Search for Guanghua Chen in:

    8. Search for Mingqing Zhu in:

    9. Search for Li Yao in:

    10. Search for Ting Xu in:

    11. Search for Xiaopeng Tian in:

    12. Search for Yang Xu in:

    13. Search for Jia Chen in:

    14. Search for Xiaming Zhu in:

    15. Search for Lei Yu in:

    16. Search for Depei Wu in:

    17. Search for Xiaowen Tang in:

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Corresponding author

    Correspondence to Xiaowen Tang.

    Supplementary information

    1. Figure S1. Changes of BM in case 1 after CAR-T-19 therapy

    2. Figure S2. Changes of BM in case 2 after CAR-T-19 therapy

    3. Figure S3. Protocol of CAR-T-19 therapy and changes of WBC, NEU, T, cytokines and CAR-T-19 copies in both patients after CAR-T-19 infusion

    4. Figure S4. CAR-T expansion in both cases in vivo

    5. Table S1. Clinical trials registered on application of CAR-T for AML patients

    6. Supplementary Figure Legends

    To obtain permission to re-use content from this article visit RightsLink.

    About this article

    Publication history

    Received

    Revised

    Accepted

    Published

    DOI

    https://doi.org/10.1038/s41409-018-0423-y